Cambridge MA (PRWEB) July 10, 2011
OPK Biotech LLC is pleased to announce that it has grown from 8 employees to over 100 since late its commencement of operations in October 2009. The Company has expanded operations into the technical manufacturing, engineering and scientific arenas as well as added finance, maintenance and administrative personnel, most of whom were residents of Massachusetts. Company’s commitment to the biotechnology industry and to the City of Cambridge and Massachusetts is also manifest in the renewal of the lease of their headquarters and manufacturing facility in Cambridge.
The Company also qualified for a grant from the IRS for $244,479 for its Qualifying Therapeutic Discovery Project - HBOC-201/cGMP Manufacturing Facility. The Company has worked with local contractors whenever possible for the modernization and streamlining of its facility and manufacturing process.
OPK Biotech LLC, Cambridge, Massachusetts, USA, has developed and manufactures two first-in-class pharmaceuticals or oxygen therapeutics: Hemopure® [hemoglobin glutamer – 250 (bovine)], or HBOC-201, for human use and Oxyglobin® [hemoglobin glutamer – 200 (bovine)], or HBOC-301, for veterinary use. Hemopure has been approved for use the treatment of acute surgical anemia in South Africa since 2001 and recently won approval in Russia for acute anemia. OPK Biotech’s veterinary product, Oxyglobin, the only oxygen therapeutic approved for use by both the European Commission and the U.S. Food and Drug Administration, is indicated for the treatment of all-cause anemia in dogs. The Company’s research strategy focuses on the further development of Hemopure in indications that may be benefitted from use of an oxygen therapeutic, such as ischemia, anemia, and trauma.